Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder

Movement Disorders

Volumn 29, Issue 14, 2014, Pages 1774-1780

  Iranzo, Alex ^a   Stockner, Heike ^b   Serradell, Mónica ^a   Seppi, Klaus ^b   Valldeoriola, Francesc ^a   Frauscher, Birgit ^b   Molinuevo, José Luis ^a   Vilaseca, Isabel ^c   Mitterling, Thomas ^b   Gaig, Carles ^a   Vilas, Dolores ^a   Santamaria, Joan ^a   Högl, Birgit ^b   Tolosa, Eduard ^a   Poewe, Werner ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Follow up; Parkinson's disease; REM sleep behavior disorder; Substantia nigra echogenicity; Transcranial sonography

Indexed keywords

AGED; COHORT ANALYSIS; COMPLICATION; DOPPLER ECHOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PARKINSON DISEASE; PROCEDURES; PROSPECTIVE STUDY; REM SLEEP BEHAVIOR DISORDER; SUBSTANTIA NIGRA;

AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; REM SLEEP BEHAVIOR DISORDER; SUBSTANTIA NIGRA; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84918517746     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26055     Document Type: Article

References (36)

1. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044-1055.
2. Berg D. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm 2011;118:613-619.
3. Vlaar AMM, Bouwmans A, Mess WH, Tromp SC, Weber WEJ. Transcranial duplex in the differential diagnosis of parkinsonian syndromes. J Neurol 2009;256:530-538.
4. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R. Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease. Mov Disord 2006;2007:48-54.
5. Busse K, Heilmann R, Kleinscmidt S, et al. Value of combined midbrain sonography, olfactory and motor function in assessment in the differential diagnosis of early Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:441-447.
6. Berg D, Behnke S, Seppi K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013;28:216-219.
7. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of substantia nigra in Parkinson's disease. Mov Disord 2005;20:383-385.
8. Behnke S, Runkel A, Al-Sibai Kassar H, et al. Long-term course of substantia nigra hyperechogenicity in Parkinson's disease. Mov Disord 2013;28:455-459.
9. Mahlknecht P, Stockner H, Nocker M, et al. A follow-up study of substantia nigra in healthy adults. Mov Disord 2012;27:1192-1194.
10. Boeve B. REM sleep behavior disorder. Ann N Y Acad Sci 2010;1184:15-54.
11. Arnulf I. REM sleep behavior disorder: motor manifestations and pathophysiology. Mov Disord 2012;27:677-689.
12. Iranzo A, Tolosa E, Gellpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12:443-453.
13. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder (IBD): 16 year update on a previously reported series. Sleep Med 2013;14:744-748.
14. Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 9:e89741. doi:10.1371/journal.pone.0089741.
15. Stockner H, Iranzo A, Seppi K, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009;24:1906-1909.
16. Iranzo A, Lomeña F, Stockner H, et al, for the Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2010;9:1070-1077.
17. Iwanami M, Miyamoto T, Miyamoto M, Hirata K, Takada E. Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med 2010;11:361-365.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
19. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-1872.
20. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
21. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 2011;69:811-818.
22. Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10:797-805.
23. Iranzo A, Serradell M, Vilaseca I, et al. Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 2013;19:600-604.
24. Berg D, Becker G, Zeiller B, et al. Vulnerability of the nigrostriatal system as detected by transcranial sound. Neurology 1999;53:1026-1031.
25. Berg D, Siekfer C, Ruprecht-Dörfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001;56:13-17.
26. Berg D, Roggendorf W, Schröder U, et al. Echogenicity of the substantia nigra. Arch Neurol 2002;59:999-1005.
27. Berg D, Seppi K, Liepelt I, et al. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 2010;25:1464-1469.
28. Liepelt I, Behnke S, Schweitzer K, et al. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging 2011;32:1599-1606.
29. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007;130:1799-1807.
30. Schrag A. Epidemiology of movement disorders. In: Jankovic JJ, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Philadelphia: Lippincott Williams & Wilkins; 2002:73-89.
31. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-689.
32. Ressner P, Skoloudik D, Hlustik P, Kanovsky P. Hyperechogenicity of the substantia nigra in Parkinson's disease. J Neuroimaging 2007;17:164-167.
33. Spiegel J, Hellwig D, Möllers M, et al. Transcranial sonography and [123I]-FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006;129:1188-1193.
34. Walter U, Dressler D, Wolters A, Wittstock M, Greim B, Benecke R. Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. J Neurol 2006;253:448-454.
35. Behnke S, Berg D, Naumann M, Becker G. Differentation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005;76:423-425.
36. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008;7:417-424.